2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program

BACKGROUND: Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line therapy. We evaluated the in vitro activity of RZF, caspofungin...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677430/
http://dx.doi.org/10.1093/ofid/ofad500.1738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677430/
http://dx.doi.org/10.1093/ofid/ofad500.1738

Ejemplares similares